Indeed, we observed an increase in the expression levels of both RAS‐GTP and pERK in FBXO42 KO samples treated and untreated with trametinib, compared to the control cells (Figure 5a,b and Figure S2), suggesting that KO of FBXO42 in NRAS‐mutant melanoma cells leads to MAPK pathway activation. The gene discussed is NRAS; the disease is melanoma.